Healthcare Industry News: allergic rhinitis
News Release - March 20, 2006
Kurve Technology Signs Agreement With Schering-Plough CorporationNasal Drug Delivery Firm Inks Deal With Global Health Care Company
BOTHELL, Wash., March 20 (HSMN NewsFeed) -- Kurve Technology, Inc., a leader in nasal drug delivery devices, today announced it has entered into an agreement with Schering-Plough Corporation.
"We are delighted to partner with a global pharmaceutical leader," said Marc Giroux, Chairman and Chief Executive Officer of Kurve Technology, Inc. "The value of our Controlled Particle Dispersion(TM) technology platform and ViaNase(TM) device line continues to grow and we are excited about working with the team at Schering-Plough."
Incorporating patented Controlled Particle Dispersion(TM) and intelligent nasal drug delivery technologies, Kurve Technology's ViaNase electronic atomizer intranasally delivers topical, systemic and nose-to-brain medical therapies with greater efficacy and efficiency than traditional nasal delivery devices such as spray pumps. ViaNase is the first nasal drug delivery device that saturates the entire nasal cavity, allowing potential delivery to the paranasal sinuses. In addition, ViaNase limits peripheral deposition of pharmaceutical formulations into the lungs or stomach. Kurve Technology most recent device offering -- ViaNase ID(TM) -- incorporates drug pedigree confirmation, lock-out technology, and an electronic display to curb counterfeit drug use and abuse while improving patient compliance.
About Kurve Technology, Inc.
Kurve Technology, Inc. offers pharmaceutical companies innovative nasal delivery systems for local and systemic medical therapies. Kurve's Controlled Particle Dispersion (CPD)(TM) technology intranasally delivers formulations with far greater efficacy and efficiency than traditional methods. The ViaNase product line of intelligent atomizers incorporates CPD to deliver a wide range of compounds, aiding the more than 200 million patients who suffer from such medical conditions as allergic rhinitis, chronic rhinosinusitis, sexual dysfunction, migraine headache, obesity, and CNS disease. Kurve Technology is headquartered in Bothell, WA with an office in Research Triangle Park, NC. For additional information, please visit www.kurvetech.com.
Source: Kurve Technology
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.